Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Thrombus formation is a feared complication after congenital heart surgery. We aimed to clarify the clinical characteristics associated with thrombus formation after the Norwood procedure.

Methods: All neonates who underwent the Norwood procedure between 2001 and 2022 were reviewed. The incidence and location of thrombus were evaluated. Risk factors for thrombus formation and its impact on survival were analyzed.

Results: Among 360 patients who were included, thrombus formation was detected in 42 patients (11.7 %) during the postoperative in-hospital period, with a median of 12 (range: 5-30) postoperative days. The most common site of thrombus was the superior vena cava in 9 (2.5 %) patients, followed by the right atrium in 8 (2.2 %). Patients who received a right ventricle to pulmonary artery conduit had a higher incidence of thrombus than those who received a modified Blalock-Taussig-Thomas shunt (16.4 vs. 7.7 %, p = 0.011). Patients with thrombus formation had a longer stay in the intensive care unit (ICU), than those without (median 21 vs. 13 days, p = 0.018). Survival after ICU discharge was lower in patients with thrombus than those without (57, 54, and 54 % vs 73, 71, and 70 % at 2, 4, and 6 years, respectively; p = 0.032). Restrictive atrial septal defect was identified as an independent risk for thrombus (odds ratio: 2.61; p = 0.005).

Conclusions: Thrombus formation was observed in 12 % of the patients during the hospital stay after the Norwood procedure and was associated with prolonged recovery and high mortality. A restrictive atrial septal defect was identified as a risk factor for thrombus formation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053980PMC
http://dx.doi.org/10.1016/j.ijcchd.2025.100575DOI Listing

Publication Analysis

Top Keywords

thrombus formation
32
thrombus
13
norwood procedure
12
formation norwood
8
risk factors
8
patients thrombus
8
restrictive atrial
8
atrial septal
8
septal defect
8
defect identified
8

Similar Publications

Purpose: To assess the utility of inflammatory marker levels in defining orbital cellulitis (OC) severity.

Methods: A retrospective cohort study was conducted at 2 tertiary care centers using a medical record search of billing codes from January 1, 2000, to January 1, 2023. Patients were categorized into 2 cohorts-uncomplicated OC and OC with complication [subperiosteal abscess (SPA), orbital abscess (OA), or cavernous sinus thrombosis (CST)].

View Article and Find Full Text PDF

Organelle stresses and energetic metabolisms promote endothelial-to-mesenchymal transition and fibrosis via upregulating FOSB and MEOX1 in Alzheimer's disease.

Front Mol Neurosci

August 2025

Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Lemole Center for Integrated Lymphatics and Vascular Research, Temple University, Philadelphia, PA, United States.

Introduction: Endothelial-to-mesenchymal transition (EndoMT), cell death, and fibrosis are increasingly recognized as contributing factors to Alzheimer's disease (AD) pathology, but the underlying transcriptomic mechanisms remain poorly defined. This study aims to elucidate transcriptomic changes associated with EndoMT, diverse cell death pathways, and fibrosis in AD using the 3xTg-AD mouse model.

Methods: Using RNA-seq data and knowledge-based transcriptomic analysis on brain tissues from the 3xTg-AD mouse model of AD.

View Article and Find Full Text PDF

Factor XIII (FXIII) deficiency is a rare coagulopathy with an estimated prevalence of approximately 1 in 1 to 2 million, affecting males and females with equal frequency. FXIII plays a critical role in hemostasis by stabilizing fibrin clots through covalent cross-linking of fibrin monomers, thereby conferring mechanical resistance and durability to the clot structure. Clinically, FXIII deficiency presents with a spectrum of hemorrhagic manifestations including bleeding from the umbilical cord, intracranial hemorrhage, recurrent miscarriages, menorrhagia, epistaxis, gingival bleeding, and poor wound healing.

View Article and Find Full Text PDF

Unopposed platelet activation can be associated with pathologic thrombosis. An intact growth arrest-specific gene 6 (GAS6)/Mer receptor tyrosine kinase (MERTK) signaling pathway contributes importantly to potentiating platelet activation triggered by molecular agonists ex vivo and thrombus stabilization in vivo. We describe, herein, the inhibition of platelet function and stable thrombus formation conferred by iMer, a naturally occurring MERTK splice variant, that acts as a GAS6 decoy receptor and decreases phosphorylation of MERTK.

View Article and Find Full Text PDF

Immunomodulation and Thrombolytic Approaches in the Management of Deep Vein Thrombosis and Pulmonary Embolism.

Cardiol Cardiovasc Med

August 2025

Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are key initiating events in the development of venous thromboembolism (VTE), a condition associated with significant morbidity, mortality, and long-term complications. While traditional therapies have focused on anticoagulation and thrombolysis, current evidence describes the pivotal role of immune pathways in the pathogenesis and progression of thrombosis. This review explores the multifaceted mechanisms underlying DVT and PE, emphasizing the contribution of inflammation, leukocyte activation, and immuno-thrombosis to thrombus formation and embolization.

View Article and Find Full Text PDF